

Brand and generics companies unite to pressure FDA: they want the agency to drop its safety-label plan and adopt their alternative

Barlas S.

Pharmacy and therapeutics

2015; 40(8):501-503

ARTICLE IDENTIFIERS

DOI: unavailable

PMID: 26236138

PMCID: PMC4517532

JOURNAL IDENTIFIERS

LCCN: not available

pISSN: 1052-1372

eISSN: not available

OCLC ID: 22095729

CONS ID: not available

US National Library of Medicine ID: 9015516

This article was identified from a query of the SafetyLit database.